Has Jane Mayrin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $627,863 in general payments to Jane Mayrin, MD across 1,754 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jane Mayrin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jane Mayrin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jane Mayrin, MD

Endocrinology, Diabetes & Metabolism · Philadelphia, PANPI 1467679738

Payments from drug & device makers

$627,863in general payments, 2019–2025

Across 1,754 payments — averaging $357.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$273K
Novo Nordisk$163K
AstraZeneca$65K
Sanofi-aventis U.S. LLC$60K
Amarin Pharma, Inc.$36K
Johnson & Johnson$13K
plus $19K from 51 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	580	$272,962
Novo Nordisk	246	$162,583
AstraZeneca(2 entities)	150	$65,166
Sanofi-aventis U.S. LLC	143	$60,039
Amarin Pharma, Inc.	51	$35,673
Johnson & Johnson	17	$12,891
Medtronic(2 entities)	38	$4,710
Intuity Medical Inc	10	$2,351
Amgen(2 entities)	56	$1,080
Boehringer Ingelheim	39	$953
Corcept Therapeutics	33	$858
Bayer	56	$819
Radius Health, Inc.	35	$796
Mannkind Corporation	39	$775
Xeris Pharmaceuticals, Inc.	39	$745
AbbVie	12	$673
Amneal Pharmaceuticals LLC	3	$532
Novartis	27	$476
Aimmune Therapeutics, Inc.	14	$366
BD	15	$329
Dexcom, Inc.	12	$304
Antares Pharma, Inc.	14	$276
Nestle Healthcare Nutrition Inc.	7	$211
Astellas Pharma US Inc	6	$199
Amphastar Pharmaceuticals, Inc.	10	$197
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	14	$190
Almatica Pharma LLC	8	$152
BETA Bionics, Inc.	6	$125
Recordati_rare_diseases_inc.	7	$121
Esperion Therapeutics, Inc.	6	$113
Abbott	5	$104
Embecta Corp.	3	$96
Tolmar, Inc.	5	$81
Clarus Therapeutics Inc.	4	$80
Tandem Diabetes Care, Inc.	4	$78
Madrigal Pharmaceuticals	2	$64
Kyowa Kirin, Inc.	3	$62
Halozyme Inc	4	$61
Soleno Therapeutics, Inc.	3	$59
Ultragenyx Pharmaceutical Inc.	3	$57
Ascendis Pharma Endocrinology Inc	2	$47
Chiesi USA, Inc.	2	$45
Vifor Pharma, Inc.	2	$45
Vivus LLC	2	$42
Insulet Corporation	2	$42
Averitas Pharma Inc.	2	$33
Endo Pharmaceuticals Inc.	2	$29
OPKO Pharmaceuticals, LLC	2	$29
Acerus Pharmaceuticals Corporation	1	$23
Ipsen Biopharmaceuticals, Inc	1	$18
Zealand Pharma US, Inc.	1	$16
GRT US Holding, Inc.	1	$15
Takeda Pharmaceuticals U.S.A., Inc.	1	$15
Companion Medical, Inc.	1	$15
Sequel Med Tech, LLC	1	$14
Sanofi US Services Inc.	1	$14
Kowa Pharmaceuticals America, Inc.	1	$13

How this compares

$627,863 in reported general payments places this provider in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

See all endocrinology, diabetes & metabolism providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$350,898

Medicare patients

965

Services billed

4,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Philadelphia

Mona Al MukaddamPhiladelphia$3.9M
Serge JabbourPhiladelphia$3.1M
Mihaela BiscoveanuPhiladelphia$1.5M
Barbara SimonPhiladelphia$1M
Mitchell LazarPhiladelphia$1M
Intekhab AhmedPhiladelphia$926K
Michael RickelsPhiladelphia$606K
Steven NagelbergPhiladelphia$483K
Kevin WilliamsPhiladelphia$137K
Laura YoungPhiladelphia$99K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →